Ammonia toxicity and its prevention in inherited defects of the urea cycle

Diabetes, Obesity and Metabolism

Volumn 11, Issue 9, 2009, Pages 823-835

  Walker, Valerie ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Alternative pathway therapies; Ammonia toxicity; OTC deficiency; Sodium benzoate; Sodium phenylacetate; Sodium phenylbutyrate; Urea cycle; Urea cycle defects

Indexed keywords

4 AMINOBUTYRIC ACID; 4 PHENYLBUTYRIC ACID; ACETYLCHOLINE; AMMONIA; AMPA RECEPTOR; ARGINASE; ARGININE; ARGININOSUCCINATE LYASE; ARGININOSUCCINATE SYNTHASE; BENZOIC ACID; CARBAMOYL PHOSPHATE SYNTHASE; FLUMAZENIL; GLUTAMATE ACETYLTRANSFERASE; GLUTAMIC ACID; GLUTAMINE; ION CHANNEL; MAGNESIUM SULFATE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITROGEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORNITHINE ASPARTATE; ORNITHINE CARBAMOYLTRANSFERASE; PHENYLACETIC ACID; SEROTONIN; SILDENAFIL;

AMMONIA BLOOD LEVEL; AMMONIA FORMATION; ANOREXIA; ATAXIA; BRAIN DAMAGE; CLINICAL FEATURE; CLINICAL TRIAL; DETOXIFICATION; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; ENZYME DEFICIENCY; GENETIC COUNSELING; GENETIC DISORDER; HUMAN; HYPERAMMONEMIA; HYPOKALEMIA; IRRITABILITY; LETHARGY; LIVER TRANSPLANTATION; LOADING DRUG DOSE; LOW DRUG DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; POLYARTERITIS NODOSA; PRENATAL DIAGNOSIS; REVIEW; SIDE EFFECT; SOMNOLENCE; TACHYPNEA; TINNITUS; TREMOR; UREA CYCLE; VISUAL DISORDER; VOMITING;

ADULT; AMMONIA; ANIMALS; ARGININE; GENE THERAPY; HUMANS; HYPERAMMONEMIA; ORNITHINE CARBAMOYLTRANSFERASE DEFICIENCY DISEASE; UREA; UREA CYCLE DISORDERS, INBORN;

EID: 69249202553     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01054.x     Document Type: Review

References (119)

1. Brusilow SW, Horwich AL. Urea cycle enzymes. In Scriver CR, Beaudet D, Valle D, Sly WS eds. The Metabolic and Molecular and Bases of Inherited Disease. 8th edn. New York: McGraw-Hill, 2001; 1909-1961.
2. Summar M, Tuchman M. Proceedings of a consensus conference for the management of patients with urea cycle disorders. J Pediatr 2001; 138: S6-S10.
3. Walker V. Hyperammonaemia. In Clayton BE, Round JM eds. Clinical Biochemistry of the Sick Child. Oxford: Blackwell Scientific Publications, 1994; 100-120.
4. Brusilow SW, Maestri NE. Urea cycle disorders: Diagnosis, pathophysiology, and therapy. Adv Pediatr 1996; 43: 127-170.
5. Feillet F, Leonard JV. Alternative pathway therapy for urea cycle disorders. J Inherit Metab Dis 1998; 21 (Suppl. 1): 101-111.
6. Young VR, El-Khoury AE, Ragoso CA, Forslund AH, Hambraeus L. Rates of urea production and hydrolysis and leucine oxidation change linearly over widely varying protein intakes in healthy adults. J Nutr 2000; 130: 761-766.
7. Meijer AJ, Lamers WH, Chamuleau RAFM. Nitrogen metabolism and ornithine cycle function. Physiol Rev 1990; 70: 701-748.
8. Souba WW. Interorgan ammonia metabolism in health and disease: A surgeon's view. J Parent Ent Nutr 1987; 11: 569-579.
9. Cooper AJL, Plum P. Biochemistry and physiology of brain ammonia. Physiol Rev 1987; 67: 440-519.
10. Warter JM, Brandt C, Marescaux C et al. The renal origin of sodium valproate-induced hyperammonemia in fasting humans. Neurology 1983; 33: 1136-1140.
11. Windmueller HG, Spaeth AE. Respiratory fuels and nitrogen metabolism in vivo in small intestine of fed rats. J Biol Chem 1980; 255: 107-112.
12. Windmueller HG. Glutamine utilization by the small intestine. In Meister A ed. Advances in Enzymology. New York: John Wiley, 1982; 201-237.
13. Mounger EJ, Branson AD. Ammonia encephalopathy secondary to ureterosigmoidostomy: A case report. J Urol 1972; 108: 411-412.
14. Jungermann K. Functional heterogeneity of periportal and perivenous hepatocytes. Enzyme 1986; 35: 161-180.
15. Marcaggi P, Coles JA. Ammonium in nervous tissue: Transport across cell membranes, fluxes from neurons to glial cells, and role in signalling. Prog Neurobiol 2001; 64: 157-183.
16. Lockwood AH, Bolomey L, Napoleon F. Blood-brain barrier to ammonia in humans. J Cereb Blood Flow Metab 1984; 4: 516-522.
17. Warren KS. The differential toxicity of ammonium salts. J Clin Invest 1958; 37: 497-501.
18. Butterworth RF. Effects of hyperammonaemia on brain function. J Inherit Metab Dis 1998; 21 (Suppl. 1): 6-20.
19. Felipo V, Butterworth RF. Neurobiology of ammonia. Prog Neurobiol 2002; 67: 259-279.
20. Gropman AL, Summar M, Leonard JV. Neurological implications of urea cycle disorders. J Inherit Metab Dis 2007; 30: 865-869.
21. Nassogne MC, Héron B, Touati G, Rabier D, Saudubray JM. Urea cycle defects: Management and outcome. J Inherit Metab Dis 2005; 28: 407-414.
22. Voorhies TM, Ehrlich ME, Duffy TE et al. Acute hyperammonemia in the young primate: Physiologic and neuropathologic correlates. Pediatr Res 1983; 17: 970-975.
23. Michalak A, Butterworth RF. Ornithine transcarbamylase deficiency: pathogenesis of the cerebral disorder and new prospects for therapy. Metab Brain Dis 1997; 12: 171-182.
24. Harding BN, Surtees RAH. Metabolic and neurodegenerative diseases of childhood. In Love S, Louis DN, Ellison DW eds. Greenfield's Neuropathology. 8th edn. London: Hodder Arnold, 2008; 481-514.
25. Albrecht J, Norenberg MD. Glutamine: A Trojan horse in ammonia neurotoxicity. Hepatology 2006; 44: 788-794.
26. Lichter-Konecki U. Profiling of astrocyte properties in the hyperammonaemic brain: Shedding new light on the pathophysiology of the brain damage in hyperammonaemia. J Inherit Metab Dis 2008; 31: 492-502.
27. Basile AS. Direct and indirect enhancement of GABAergic neurotransmission by ammonia: Implications for the pathogenesis of hyperammonemic syndromes. Neurochem Int 2002; 41: 115-122.
28. Rama Rao KV, Chen M, Simard JM, Norenberg MD. Increased aquaporin-4 expression in ammonia-treated cultured astrocytes. Neuroreport 2003; 14: 2379-2382.
29. Larsen FS. Cerebral circulation in liver failure: Ohm's law in force. Semin Liver Dis 1996; 16: 281-292.
30. Sugden P, Newsholme E. The effect of ammonium, inorganic phosphate and potassium ions on the activity of phosphfructokinases from muscle and nervous tissues of vertebrates and invertebrates. Biochem J 1975; 150: 113-122.
31. Tsacopoulos M, Magistretti PJ. Metabolic coupling between glia and neurons. J Neurosci 1996; 16: 877-885.
32. Desjardins P, Michalak A, Therrien G, Chatauret N. Butterworth RF. Increased expression of the astrocytic/endothelial cell glucose transporter (and water channel) protein GLUT-1 in relation to brain glucose metabolism and edema in acute liver failure. Hepatology 2001; 34: 253.
33. Lai J, Cooper AJL. Brain α -ketoglutarate dehydrogenase complex: kinetic properties, regional distribution and effects of inhibitors. J Neurochem 1986; 47: 1376-1386.
34. Leonard JV. Disorders of the urea cycle and related enzymes. In: Saudubray J-M, van den Berghe G, Walter JH eds. Inborn Metabolic Diseases 4th edn. Heidelberg: Springer Medizin Verlag, 2006; 263-272.
35. Nagata N, Matsuda I, Oyanagi K. Estimated frequency of urea cycle enzymopathies in Japan. Am J Med Genet 1991; 39: 228-229.
36. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia 1969-1996. Pediatrics 2000; 105: E10.
37. Wilcken B. Problems in the management of urea cycle disorders. Mol Genet Metab 2004; 81: S86-S91.
38. Tuchman M, Morizono H, Rajagopal BS, Plante RJ, Allewell NM. The biochemical and molecular spectrum of ornithine transcarbamylase deficiency. J Inherit Metab Dis 1998; 21 (Suppl. 1): 40-58.
39. Yamaguchi S, Brailey LL, Morizono H, Bale AE, Tuchman M. Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. Hum Mutat 2006; 27: 626-632.
40. Arranz JA, Riudur E, Marco-Marín C, Rubio V. Estimation of the total number of disease-causing mutations in ornithine transcarbamylase (OTC) deficiency. Value of the OTC structure in predicting a mutation pathogenic potential. J Inherit Metab Dis 2007; 30: 217-226.
41. Tuchman M, Jaleel N, Morizono H, Sheehy L, Lynch MG. Mutations and polymorphisms in the human ornithine transcarbamylase gene. Hum Mutat 2002; 19: 93-107.
42. Rohininath T, Costello DJ, Lynch T, Monavari A, Tuchman M, Treacy EP. Fatal presentation of ornithine transcarbamylase deficiency in a 62-year-old man and family studies. J Inherit Metab Dis 2004; 27: 285-288.
43. Nicolaides P, Liebsch D, Dale N, Leonard J, Surtees R. Neurological outcome of patients with ornithine carbamoyltransferase deficiency. Arch Dis Child 2002; 86: 54-56.
44. Maestri NE, Lord CR, Glynn M, Bale A, Brusilow SW. The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency. Medicine 1998; 77: 389-397.
45. Gyato K, Wray J, Huang ZJ, Yudkoff M, Batshaw ML. Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. Ann Neurol 2004; 55: 80-86.
46. Wilson BE, Hobbs WN, Newmark JJ, Farrow SJ. Rapidly fatal hyperammonaemic coma in adults-urea cycle enzyme deficiency. West J Med 1994; 161: 166-168.
47. Felig DM, Brusilow SW, Boyer JL. Hyperammonaemic coma due to parenteral nutrition in a woman with heterozygous ornithine transcarbamylase deficiency. Gastroenterology 1995; 109: 282-284.
48. Triveda M, Zafar S, Spalding MJ, Jonnalagadda S. Ornithine transcarbamylase deficiency unmasked because of gastrointestinal bleeding. J Clin Gastroenterol 2001; 32: 340-343.
49. Honeycutt D, Callahan K, Rutledge L, Evans B. Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. Neurology 1992; 42: 666.
50. Eze E, Workman M, Donley B. Hyperammonemia and coma developed by a woman treated with valproic acid for affective disorder. Psychiatric Serv 1998; 49: 1358-1359.
51. Ellaway CJ, Bennetts B, Tuck RR, Wilcken B. Clumsiness, confusion, coma, and valproate. Lancet 1999; 353: 1408.
52. Cordero DR, Baker J, Dorinzi D, Toffle R. Ornithine transcarbamylase deficiency in pregnancy. J Inherit Metab Dis 2005; 28: 237-240.
53. Arn PH, Hauser ER, Thomas GH, Herman G, Hess D, Brusilow SW. Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus. New Engl J Med 1990; 322: 1652-1655.
54. Peterson DE. Acute postpartum mental status change and coma caused by previously undiagnosed ornithine transcarbamylase deficiency. Obstet Gynaecol 2003; 102: 1212-1215.
55. Uchino T, Endo F, Matsudo I. Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis 1998; 21 (Suppl. 1): 151-159.
56. Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 2007; 356: 2282-2292.
57. Becroft DMO, Phillips LI, Simmonds HA. Hereditary orotic aciduria: long-term therapy with uridine and a trial of uracil. J Pediatr 1969; 75: 885-891.
58. Sebesta I, Fairbanks LD, Davies PM, Simmonds HA, Leonard JV. The allopurinol loading test for identification of carriers for ornithine carbamoyl transferase deficiency: Studies in a healthy control population and females at risk. Clin Chim Acta 1994; 224: 45-54.
59. Potter M, Hammond JW, Sim KG, Green AK, Wilcken B. Ornithine carbamoyltransferase deficiency: Improved sensitivity of testing for protein tolerance in the diagnosis of heterozygotes. J Inherit Metab Dis 2001; 24: 5-14.
60. Hauser ER, Finkelstein JE, Valle D, Brusilow SW. Allopurinol-induced orotidinuria. New Engl J Med 1990; 322: 1641-1645.
61. Grünewald S, Fairbanks L, Genet S et al. How reliable is the allopurinol load in detecting carriers for ornithine transcarbamylase deficiency? J Inherit Metab Dis 2004; 27: 179-186.
62. Lee B, Yu H, Jahoor F, O'Brien W, Beaudet AL, Reeds P. In vivo urea cycle flux distinguishes and correlates with phenotypic severity in disorders of the urea cycle. Proc Natl Acad Sci USA 2000; 97: 8021-8026.
63. Scaglia F, Zheng Q, O'Brien WE et al. An integrated approach to the diagnosis and prospective management of partial ornithine transcarbamylase deficiency. Pediatrics 2002; 109: 150-152.
64. Yudkoff M, Daikhin Y, Nissim I et al. In vivo nitrogen metabolism in ornithine transcarbamylase deficiency. J Clin Invest 1996; 98: 2167-2173.
65. The Urea Cycle Disorders Conference Group. Consensus statement from a conference for the management of patients with urea cycle disorders. J Pediatr 2001; 138 (Suppl.): S1-S5.
66. Singh RH. Nutritional management of patients with urea cycle disorders. J Inherit Metab Dis 2007; 30: 880-887.
67. Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: Twenty years later. J Pediatr 2001; 138 (Suppl.): S46-S55.
68. British Inherited Metabolic Disease Group. Guidelines; BIMDG emergency protocols 14 and 15- Hyperammonaemia: Urea cycle disorders. BIMDG. 2008. Available from URL: http://www.BIMDG.com/. Accessed 3 January 2009.
69. Pupim LB, Flakoll PJ, Ikizler TA. Protein homeostasis in chronic hemodialysis patients. Curr Opin Clin Nutr Metab Care 2004; 7: 89-95.
70. Ikizler TA, Pupim LB, Brouillette JR et al. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab 2002; 282: E107-E116.
71. Leonard JV. The nutritional management of urea cycle disorders. J Pediatr 2001; 138 (Suppl.): S40-S45.
72. Brusilow SW, Valle DL, Batshaw M. New pathways of nitrogen excretion in inborn errors of urea synthesis. Lancet 1979; 2: 452-454.
73. Brusilow S, Tinker J, Batshaw ML. Amino acid acylation: A mechanism of nitrogen excretion in inborn errors of urea synthesis. Science 1980; 207: 659-661.
74. Brusilow SW, Batshaw ML. Arginine therapy of argininosuccinase deficiency. Lancet 1979; 1: 124-127.
75. Barshop BA, Breuer J, Holm J, Leslie J, Nyhan WL. Excretion of hippuric acid during sodium benzoate therapy in patients with hyperglycinaemia or hyperammonaemia. J Inherit Metab Dis 1989; 12: 72-79.
76. Zimmerman L, Jörnvall H, Bergström J. Phenylacetylglutamine and hippuric acid in uremic and healthy subjects. Nephron 1990; 55: 265-271.
77. Kasumov T, Brunengraber LL, Comte B et al. New secondary metabolites of phenylbutyrate in humans and rats. Drug Metab Dispos 2004; 32: 10-19.
78. Piscitelli SC, Thibault A, Figg WD et al. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J Clin Pharmacol 1995; 35: 368-373.
79. MacArthur RB, Altincatal A, Tuchman M. Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and a continuous infusion to healthy adult volunteers. Mol Genet Metab 2004; 81: S67-S73.
80. Thibault A, Cooper MR, Figg WD et al. A phase 1 and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 1994; 54: 1690-1694.
81. Whitington PF, Alonso EM, Boyle JT et al. Liver transplantation for the treatment of urea cycle disorders. J Inherit Metab Dis 1998; 21 (Suppl. 1): 112-118.
82. Zimmermann A, Bachmann C, Baumgartner R. Severe liver fibrosis in argininosuccinic aciduria. Arch Pathol Lab Med 1986; 110: 136-140.
83. Lee B, Goss J. Long-term correction of urea cycle disorders. J Pediatr 2001; 138 (Suppl): S62-S71.
84. Leonard JV, McKiernan PJ. The role of liver transplantation in urea cycle disorders. Mol Genet Metab 2004; 81: S74-S78.
85. Noujaim HM, Mayer DA, Buckles JA et al. Techniques for and outcome of liver transplantation in neonates and infants weighing up to 5 kg. J Pediatr Surg 2002; 37: 159-164.
86. Rabier D, Narcy C, Bardet J et al. Arginine remains an essential amino acid after liver transplantation in urea cycle enzyme deficiencies. J Inherit Metab Dis 1991; 14: 277-280.
87. Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis 2006; 29: 431-435.
88. Das AM, Illsinger S, Luecke T et al. Intrauterine benzoate-loading and postpartal hepatocyte transfusion: New therapeutic modalities in urea cycle defects (UCD): First experience. J Inherit Metab Dis 2007; 30 (Suppl. 1): 83.
89. Meyberg J, Hoerster F, Lindner M et al. Liver cell transplantation (LCT) for carbamoylphosphate synthase 1 (CPS1) deficiency and citrullinaemia. J Inherit Metab Dis 2007; 30 (Suppl. 1): 83.
90. Raper SE, Wilson JM, Yudkoff M, Robinson MB, Ye X, Batshaw ML. Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency. J Inherit Metab Dis 1998; 21 (Suppl. 1): 119-137.
91. Patejunas G, Lee B, Dennis JA et al. Evaluation of gene therapy for citrullinaemia using murine and bovine models. J Inherit Metab Dis 1998; 21 (suppl 1): 138-150.
92. Editorial. Gene therapy-a loss of innocence. Nat Med 2000; 6: 1.
93. Kim S, Paik WK, Cohen PP. Ammonia intoxication in rats: Protection by N-carbamoyl-L-glutamate plus arginine. Proc Natl Acad Sci USA 1972; 69: 3530-3533.
94. Bachmann C, Colombo JP, Jaggi K. N-Acetylglutamate synthetase (NAGS) deficiency: Diagnosis, clinical observations and treatment. Adv Exp Med Biol 1982; 153: 39-45.
95. Caldovic L, Morizono H, Daikhin Y et al. Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate. J Pediatr 2004; 145: 552-554.
96. Kuchler G, Rabier D, Poggi-Travert F et al. Therapeutic use of carbamylglutamate in the case of carbamoyl-phosphate synthase deficiency. J Inherit Metab Dis 1996; 19: 220-222.
97. Nordenström A, Halldin M, Hallberg B, Alm J. A trial with N-carbamylglutamate may not detect all patients with NAGS deficiency and neonatal onset. J Inherit Metab Dis 2007; 30: 1-5.
98. Whitelaw A, Bridges S, Leaf A, Evans D. Emergency treatment of neonatal hyperammonaemic coma with mild systemic hypothermia. Lancet 2001; 358: 36-38.
99. Marcaida G, Felipo V, Hermenegildo C, Minana MD, Grisolia S. Acute ammonia toxicity is mediated by NMDA type of glutamate receptors. FEBS Lett 1992; 296: 67-68.
100. Vogels BA, Maas MA, Daalhuisen J, Quack G, Chamuleau RA. Memantine, a noncompetitive NMDA receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats. Hepatology 1997; 25: 820-827.
101. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006; 5: 160-170.
102. Chung C, Gottstein J, Blei AT. Indomethacin prevents the development of experimental ammonia-induced brain edema in rats after portacaval anastomosis. Hepatology 2001; 34: 249-254.
103. Kircheis G, Nilius R, Held C et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study. Hepatology 1997; 25: 1351-1360.
104. Rose C, Michalak A, Pannunzio P et al. L-Ornithine-L-aspartate in experimental portal-systemic encephalopathy: Therapeutic efficacy and mechanism of action. Metab Brain Dis 1998; 13: 147-157.
105. Pomier-Layrargues G, Giguère J-F, Lavoie J et al. Flumazenil in cirrhotic patients with hepatic coma: A randomized double-blind placebo-controlled cross-over trial. Hepatology 1994; 19: 32-37.
106. Häberle J, Koch HG. Genetic approach to prenatal diagnosis in urea cycle defects. Prenat Diagn 2004; 24: 378-383.
107. Bachmann C, Braissant O, Villard A-M, Boulat O, Henry H. Ammonia toxicity to the brain and creatine. Mol Genet Metab 2004; 81: S52-S57.
108. Michalak A, Rose C, Butterworth J, Butterworth RF. Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure. Hepatology 1996; 24: 908-913.
109. Robinson MB, Hopkins K, Batshaw ML, McLaughlin BA, Heyes MP, Oster-Granite ML. Evidence of excitotoxicity in the brain of the ornithine carbamoyltransferase deficient sparse fur mouse. Brain Res Dev Brain Res 1995; 90: 35-44.
110. 3H]MK801 binding sites in brain in congenital ornithine transcarbamylase deficiency. Metab Brain Dis 1995; 10: 249-255.
111. Hermenegildo C, Montoliu C, Llansola M et al. Chronic hyperammonemia impairs the glutamate-nitric oxide-cyclic GMP pathway in cerebellar neurons in culture and in the rat in vivo. Eur J Neurosci 1998; 10: 3201-3209.
112. Itzhak Y, Roig-Cantisano A, Dombra RS, Norenberg MD. Acute liver failure and hyperammonaemia increase peripheral-type benzodiazepine receptor binding and pregnenolone synthesis in mouse brain. Brain Res 1995; 705: 345-348.
113. Batshaw ML, Hyman SL, Mellits ED, Thomas GH, DeMuro R, Coyle JT. Behavioral and neurotransmitter changes in the urease-infused rat: A model of congenital hyperammonemia. Pediatr Res 1986; 20: 1310-1315.
114. 2 receptor changes in congenital ornithine transcarbamylase deficiency. Pediatr Res 1996; 40: 25-28.
115. Saheki T, Kobayashi K, Iijima M et al. Adult-onset type 11 citrullinaemia and idiopathic neonatal hepatitis caused by citrin deficiency: Involvement of the aspartate glutamate carrier for urea synthesis and maintenance of the urea cycle. Mol Genet Metab 2004; 81 (Suppl. 1): S20-S26.
116. Häberle J, Gorg B, Rutsch F et al. Congenital glutamine deficiency with glutamine synthetase mutations. N Engl J Med 2005; 353: 1926-1933.
117. Simell O, Sipila I, Rajantie J, Valle DL, Brusilow SW. Waste nitrogen excretion via amino acid acylation: Benzoate and phenylacetate in lysinuric protein intolerance. Pediatr Res 1986; 20: 1117-1121.
118. Batshaw ML, Brusilow SW, Waber L et al. Treatment of inborn errors of urea synthesis. Activation of alternative pathways of waste nitrogen synthesis and excretion. N Engl J Med 1982; 306: 1387-1392.
119. Praphanphoj V, Boyadjiev SA, Waber LJ, Brusilow SW, Geraghty MT. Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonaemia. J Inherit Metab Dis 2000; 23: 129-136.